دورية أكاديمية
Efficacy and safety of Prostate stereotactic body radiotherapy for metastatic castration-resistant prostate cancer: A prospective cohort study.
| العنوان: | Efficacy and safety of Prostate stereotactic body radiotherapy for metastatic castration-resistant prostate cancer: A prospective cohort study. |
|---|---|
| المؤلفون: | Li J; Department of Urology Oncological Surgery, Chongqing University Cancer Hospital, Han Yu Road 181, 400030 Chongqing, China., Dai J; Department of Urology Oncological Surgery, Chongqing University Cancer Hospital, Han Yu Road 181, 400030 Chongqing, China., Xian P; Department of Urology Oncological Surgery, Chongqing University Cancer Hospital, Han Yu Road 181, 400030 Chongqing, China., Xiong L; Department of psychology, Chongqing University Cancer Hospital, 400030 Chongqing, China., Song Y; Department of Urology Oncological Surgery, Chongqing University Cancer Hospital, Han Yu Road 181, 400030 Chongqing, China., Tang X; Department of Urology Oncological Surgery, Chongqing University Cancer Hospital, Han Yu Road 181, 400030 Chongqing, China., Li Y; Department of Urology Oncological Surgery, Chongqing University Cancer Hospital, Han Yu Road 181, 400030 Chongqing, China., Wu Y; Radiation Therapy Center, Chongqing University Cancer Hospital, Han Yu Road 181, 400030 Chongqing, China. Electronic address: cqmdwyz@163.com., Zhou H; Department of Urology Oncological Surgery, Chongqing University Cancer Hospital, Han Yu Road 181, 400030 Chongqing, China. Electronic address: berzou@163.com., Liu N; Department of Urology Oncological Surgery, Chongqing University Cancer Hospital, Han Yu Road 181, 400030 Chongqing, China. Electronic address: 1054567372@qq.com. |
| المصدر: | Cancer treatment and research communications [Cancer Treat Res Commun] 2021; Vol. 27, pp. 100368. Date of Electronic Publication: 2021 Mar 30. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: England NLM ID: 101694651 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2468-2942 (Electronic) Linking ISSN: 24682942 NLM ISO Abbreviation: Cancer Treat Res Commun Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [London] : Elsevier, [2016]- |
| مواضيع طبية MeSH: | Radiosurgery*/adverse effects, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Prostatic Neoplasms, Castration-Resistant/*therapy, Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cystitis/etiology ; Docetaxel/administration & dosage ; Dose Fractionation, Radiation ; Follow-Up Studies ; Gonadotropin-Releasing Hormone/agonists ; Gonadotropin-Releasing Hormone/antagonists & inhibitors ; Humans ; Male ; Neoplasm Grading ; Orchiectomy ; Proctitis/etiology ; Progression-Free Survival ; Prospective Studies ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms, Castration-Resistant/blood ; Prostatic Neoplasms, Castration-Resistant/pathology ; Radiation Injuries/etiology ; Random Allocation ; Survival Rate ; Tumor Burden |
| مستخلص: | Background: The efficacy and safety of prostate SBRT in men with mCRPC is unknown. Materials and Methods: A prospective cohort study was conducted with 125 men diagnosed with mCRPC. All patients received ADT plus chemotherapy. Patients were randomly assigned to receive daily prostate SBRT (36-48 Gy in 6-8 fractions). Patients who did not receive SBRT served as controls. Results: The primary endpoints were PFS and OS. After 89 months of total follow-up, the median PFS was 13.8 months in the SBRT group (n = 61) and 12.0 months in the control group (n = 64) (HR, 0.87; 95% CI, 0.61-1.24; P = 0.249). The OS was 25.7 months in the SBRT group and 23.8 months in the control group (HR, 0.93; 95% CI, 0.65-1.33; P = 0.230). A non-significant increase in the PSA response rate (50.8% vs. 43.7%) and time to PSA progression (8.3 months vs. 7.0 months) was observed in the SBRT group compared to the control group; however, the time to symptomatic progression was significantly prolonged in the SBRT group (11.3 months) compared to the control group (8.5 months) (HR, 0.76; 95% CI, 0.53-1.08; P = 0.019). There was an 11.5% incidence of radiation cystitis and radiation rectitis in the SBRT group, and the degree and incidence of hormone-related and chemotherapy-related adverse events were similar between the two groups. Conclusion: Adding prostate SBRT significantly prolonged the time to symptomatic progression and non-significantly prolonged PFS and OS among men with mCRPC compared to treatment with ADT plus chemotherapy alone. (Copyright © 2021. Published by Elsevier Ltd.) |
| فهرسة مساهمة: | Keywords: Metastatic castration-resistant prostate cancer; Overall survival; Primary tumor; Progression-free survival; Stereotactic body radiotherapy |
| المشرفين على المادة: | 15H5577CQD (Docetaxel) 33515-09-2 (Gonadotropin-Releasing Hormone) EC 3.4.21.77 (Prostate-Specific Antigen) |
| تواريخ الأحداث: | Date Created: 20210413 Date Completed: 20211230 Latest Revision: 20211230 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1016/j.ctarc.2021.100368 |
| PMID: | 33848805 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 2468-2942 |
|---|---|
| DOI: | 10.1016/j.ctarc.2021.100368 |